Boston, MA 的 間質性肺病 臨床試驗
9 項針對 間質性肺病 的研究正在 Boston(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
招募中3 期
- Brigham and Women's Hospital, Boston
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
招募中2 期
- Tufts Medical Center, Boston
- Brigham and Women's Hospital, Boston
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
招募中
- Brigham and Women's Hospital, Boston
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
招募中2 期
- Clinical Research Site, Boston
Platform Clinical Study for Conquering Scleroderma
招募中2 期
- Massachusetts General Hospital, Boston
- Boston University (BU), Boston
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
招募中2 期
- Massachusetts General Hospital, Boston
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
招募中3 期
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
招募中觀察性研究
- Dana-Farber Cancer Institute/Boston Children's Hospital, Boston
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
招募中2 期
- Massachusetts General Hospital, Boston
其他城市的 間質性肺病 試驗
- New York City, NY18 項研究
- Philadelphia, PA16 項研究
- Los Angeles, CA14 項研究
- Kansas City, KS13 項研究
- Durham, NC13 項研究
- Charleston, SC13 項研究
- Chicago, IL12 項研究
- Houston, TX12 項研究
- Aurora, CO11 項研究
- Ann Arbor, MI11 項研究
- Phoenix, AZ9 項研究
- Salt Lake City, UT9 項研究
Boston 的其他研究
- 乳癌111 項研究
- 非小細胞肺癌90 項研究
- 癌症(所有類型)86 項研究
- 大腸直腸癌63 項研究
- 轉移性癌症63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月5日。各研究自行設定資格標準;由研究團隊決定參與者資格。